Aurinia Pharmaceuticals (AUPH) EPS (Basic) (2019 - 2026)

Aurinia Pharmaceuticals (AUPH) has 8 years of EPS (Basic) data on file, last reported at $0.26 in Q1 2026.

• Quarterly EPS (Basic) rose 54.44% year-over-year to $0.26 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.25 (up 685.46% YoY) and the FY2025 annual result came in at $2.14, up 5216.0% from the prior year.
• EPS (Basic) fell to $0.26 in Q1 2026, from $1.57 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $1.57 in Q4 2025 to a low of -$0.27 in Q1 2022.
• A 5-year average of $0.07 and a median of -$0.06 in 2022 frame the typical range for EPS (Basic).
• Annual changes were most pronounced in 2023 — EPS (Basic) plunged 48.58% — and 2025, when it jumped 15094.77%.
• Tracing AUPH's EPS (Basic) over 5 years: stood at -$0.18 in 2022, then declined by 2.31% to -$0.19 in 2023, then soared by 105.5% to $0.01 in 2024, then soared by 15094.77% to $1.57 in 2025, then plunged by 83.46% to $0.26 in 2026.
• The last three EPS (Basic) figures came in at $0.26 (Q1 2026), $1.57 (Q4 2025), and $0.24 (Q3 2025), per Business Quant data.